Several approaches are being investigated to target Tregs in cancer therapy. These include the use of monoclonal antibodies against Treg-specific markers such as CTLA-4 and CD25, small molecule inhibitors, and cytokine modulation. The goal is to reduce the suppressive activity of Tregs without causing systemic autoimmunity.
